Business Context and Reporting Period
This Form 8-K Current Report from Ocular Therapeutix, Inc. (OCUL) covers events occurring on June 18, 2021, specifically the Company's 2021 Annual Meeting of Stockholders. The filing details corporate governance actions, including the election of directors, approval of a new stock incentive plan, and an amendment to the Company's Restated Certificate of Incorporation.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial performance data. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Corporate Actions
- Authorized Share Increase: Stockholders approved an amendment to the Restated Certificate of Incorporation to increase authorized common stock from 100,000,000 to 200,000,000 shares. The amendment was filed with the Delaware Secretary of State on June 21, 2021.
- Stock Incentive Plan: Stockholders approved the 2021 Stock Incentive Plan, which was previously adopted by the Board of Directors.
- Director Elections: Antony Mattessich and Charles Warden were elected as Class I directors to serve until the 2024 Annual Meeting.
- Executive Compensation: Stockholders approved a non-binding advisory proposal regarding the compensation of named executive officers.
- Auditor Ratification: Stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021.
Voting Results Summary
| Proposal | Votes For | Votes Against | Abstain |
|---|---|---|---|
| Election of Antony Mattessich | 36,950,364 | 8,150,322 (Withheld) | N/A |
| Election of Charles Warden | 31,587,610 | 13,513,076 (Withheld) | N/A |
| Executive Compensation (Say-on-Pay) | 43,814,529 | 1,198,582 | 87,575 |
| 2021 Stock Incentive Plan | 41,748,489 | 3,274,848 | 77,349 |
| Increase Authorized Shares | 58,081,464 | 2,853,811 | 178,878 |
| Ratification of Auditor | 60,717,981 | 245,000 | 151,172 |
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, specific risks, or contingencies. It strictly reports on the outcomes of the Annual Meeting votes.
Key Facts for Investor Verification
- Verify the effective date of the Certificate of Amendment (filed June 21, 2021) and confirm the new authorized share count of 200,000,000.
- Review the full text of the 2021 Stock Incentive Plan (Exhibit 99.1) to understand dilution potential and vesting terms.
- Note the significant number of broker non-votes (16,013,467) on director elections and the executive compensation proposal, indicating shares held in street name where brokers lacked discretionary voting power.
- Confirm the tenure of newly elected directors Antony Mattessich and Charles Warden, who serve until the 2024 Annual Meeting.